The first six months of 2025 have seen Chenglai take significant steps to promote EchoLaser-based microinvasive treatments for Benign Prostatic Hyperplasia (BPH) across China.

Key milestones include:

• Sino-Italian Joint Prostate Laser Ablation Surgery Demonstration:
  An important academic event in Beijing where Italian experts collaborated with Chinese urologists to showcase live EchoLaser ablation procedures for BPH, fostering international exchange and hands-on learning.
• Participation in major urology congresses:
  Chenglai actively promoted EchoLaser technology at several high-profile urological forums, focusing on the benefits of laser-based microinvasive treatments for enlarged prostate, such as minimal trauma, quick recovery, and high patient satisfaction.

Expert training and academic discussions:
Through live demonstrations, hands-on training sessions, and specialist lectures, Chenglai helped hundreds of Chinese urologists gain practical insights into EchoLaser prostate applications.

These efforts reflect Chenglai’s dedication to improving the standard of care for BPH patients in China, making EchoLaser an increasingly recognized solution in the field of minimally invasive urology.

We look forward to seeing even greater adoption and clinical success in the coming months!